ACE2 and Microbiota
- 1 December 2015
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Cardiovascular Pharmacology
- Vol. 66 (6), 540-550
- https://doi.org/10.1097/fjc.0000000000000307
Abstract
The health of the cardiovascular and pulmonary systems is inextricably linked to the renin–angiotensin system (RAS). Physiologically speaking, a balance between the vasodeleterious (Angiotensin-converting enzyme [ACE]/Angiotensin II [Ang II]/Ang II type 1 receptor [AT1R]) and vasoprotective (Angiotensin-converting enzyme 2 [ACE2]/Angiotensin-(1-7) [Ang-(1-7)]/Mas receptor [MasR]) components of the RAS is critical for cardiopulmonary homeostasis. Upregulation of the ACE/Ang II/AT1R axis shifts the system toward vasoconstriction, proliferation, hypertrophy, inflammation, and fibrosis, all factors that contribute to the development and progression of cardiopulmonary diseases. Conversely, stimulation of the vasoprotective ACE2/Ang-(1-7)/MasR axis produces a counter-regulatory response that promotes cardiovascular health. Current research is investigating novel strategies to augment actions of the vasoprotective RAS components, particularly ACE2, in order to treat various pathologies. Although multiple approaches to increase the activity of ACE2 have displayed beneficial effects against experimental disease models, the mechanisms behind its protective actions remain incompletely understood. Recent work demonstrating a non-catalytic role for ACE2 in amino acid transport in the gut has led us to speculate that the therapeutic effects of ACE2 can be mediated, in part, by its actions on the gastrointestinal tract and/or gut microbiome. This is consistent with emerging data which suggest that dysbiosis of the gut and lung microbiomes is associated with cardiopulmonary disease. This review highlights new developments in the protective actions of ACE2 against cardiopulmonary disorders, discusses innovative approaches to targeting ACE2 for therapy, and explores an evolving role for gut and lung microbiota in cardiopulmonary health.Keywords
This publication has 133 references indexed in Scilit:
- Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patientsEuropean Heart Journal, 2012
- ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertensionCardiovascular Research, 2011
- Human oral, gut, and plaque microbiota in patients with atherosclerosisProceedings of the National Academy of Sciences of the United States of America, 2011
- Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47phox NADPH oxidase subunitCardiovascular Research, 2011
- Soluble Angiotensin-Converting Enzyme 2 in Human Heart Failure: Relation With Myocardial Function and Clinical OutcomesJournal of Cardiac Failure, 2009
- Lactobacillus fermentumME-3 – an antimicrobial and antioxidative probioticMicrobial Ecology in Health & Disease, 2009
- Angiotensin‐converting enzyme 2 in the brain: properties and future directionsJournal of Neurochemistry, 2008
- Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure: Insights Into the Endogenous Counter-Regulatory Pathway of the Renin-Angiotensin-Aldosterone SystemJournal of the American College of Cardiology, 2008
- Genetic variation in angiotensin-converting enzyme 2 gene is associated with extent of left ventricular hypertrophy in hypertrophic cardiomyopathyHuman Genetics, 2008
- Determining the transgene containment level provided by chloroplast transformationProceedings of the National Academy of Sciences of the United States of America, 2007